Clinical drug trial tracker
Every registered trial behind the experimental drugs we profile: what is reading out next, what has stopped and why, and where results have been posted. Data from ClinicalTrials.gov, retrieved Nov 19, 2026.
Search and filter trials
- Phase 4Not yet recruiting
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
- Phase 4Not yet recruiting
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
- Phase 4Recruiting
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
- Phase 3Active, not recruiting
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
- Phase 3Active, not recruiting
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- Phase 3Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
- Phase 3Recruiting
MOVE-Lp(a): Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Phase 3Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Phase 3Active, not recruiting
PREVAIL: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Phase 3Completed
Lp(a)HORIZON: Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
- Phase 3Active, not recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- Phase 3Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Phase 3Active, not recruiting
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
- Phase 3Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Phase 3Enrolling by invitation
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- Phase 3Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Phase 3Active, not recruiting
REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- Phase 3Active, not recruitingResults posted
ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- Phase 3Active, not recruiting
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
- Phase 3CompletedResults posted
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
- Phase 3Completed
ACHIEVE-4: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- Phase 3Completed
REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Phase 3CompletedResults posted
BROADWAY: Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
- Phase 3Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Phase 3Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3Completed
TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- Phase 3Recruiting
ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Phase 3Completed
TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
- Phase 3CompletedResults posted
ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Phase 3CompletedResults posted
ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Trials that list one of our profiled drugs as an intervention. Status, dates, and enrollment are as reported by sponsors to the registry; “est.” marks anticipated values. For what to look for in a result, read What Is a Primary Clinical Trial Endpoint? and What Is Statistical Significance?
Readout calendar: next 12 months
Active Phase 2 and Phase 3 trials whose primary completion date, the date the last participant is assessed for the main endpoint, falls before Nov 19, 2027. Results are usually announced weeks to months later. Most of these dates are sponsor estimates and often move.
| Primary completion | Trial | Drug | Phase | Enrollment |
|---|---|---|---|---|
| Nov 2026 (est.) | PREVAIL · NCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Obicetrapib | Phase 3 | 9,541 |
| Nov 2026 (est.) | TRIUMPH-5 · NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide | Phase 3 | 800 |
| Nov 2026 (est.) | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Sacituzumab tirumotecan | Phase 3 | 406 |
| Nov 2026 (est.) | VINCENT · NCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Obicetrapib | Phase 2 | 69 |
| Dec 2026 (est.) | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Sacituzumab tirumotecan | Phase 3 | 432 |
| Dec 2026 (est.) | NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Ivonescimab | Phase 3 | 416 |
| Dec 2026 (est.) | NCT05689853 Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | Ivonescimab | Phase 1/2 | 87 |
| Dec 1, 2026 (est.) | NCT07070466 Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Ivonescimab | Phase 2 | 40 |
| Dec 2026 (est.) | PRO-XL · NCT06568562 XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer | Zanzalintinib | Phase 2 | 32 |
| Dec 15, 2026 (est.) | STELLAR-304 · NCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Zanzalintinib | Phase 3 | 317 |
| Dec 20, 2026 (est.) | iTHYM · NCT06750952 Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial | Ivonescimab | Phase 2 | 24 |
| Dec 30, 2026 (est.) | VERITAC-3 · NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Vepdegestrant | Phase 3 | 59 |
| Dec 30, 2026 (est.) | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Sacituzumab tirumotecan | Phase 2 | 321 |
| Dec 30, 2026 (est.) | NEOINSPIRE · NCT07086326 A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC | Ivonescimab | Phase 2 | 164 |
| Dec 30, 2026 (est.) | NCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Ivonescimab | Phase 2 | 120 |
| Dec 30, 2026 (est.) | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Ivonescimab | Phase 1/2 | 110 |
| Dec 30, 2026 (est.) | NCT07108816 A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC) | Sacituzumab tirumotecan | Phase 2 | 52 |
| Dec 31, 2026 (est.) | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Sacituzumab tirumotecan | Phase 3 | 376 |
| Dec 31, 2026 (est.) | NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Ivonescimab | Phase 1/2 | 154 |
| Dec 31, 2026 (est.) | NCT06769971 Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | Ivonescimab | Phase 2 | 80 |
| Dec 31, 2026 (est.) | NCT06820762 Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | Ivonescimab | Phase 2 | 40 |
| Dec 31, 2026 (est.) | NCT07579598 ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma | Sacituzumab tirumotecan | Phase 2 | 40 |
| Dec 31, 2026 (est.) | ZENOBIA · NCT06698250 Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | Zanzalintinib | Phase 2 | 40 |
| Dec 31, 2026 (est.) | BALISTA · NCT06793332 BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | Ivonescimab, Sacituzumab tirumotecan | Phase 2 | 39 |
| Dec 31, 2026 (est.) | NCT06769295 A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC | Ivonescimab | Phase 2 | 28 |
| Jan 2027 (est.) | NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Ivonescimab | Phase 3 | 510 |
| Jan 2027 (est.) | MEDICI · NCT07614958 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days | Obicetrapib | Phase 3 | 426 |
| Jan 2027 (est.) | NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Ivonescimab | Phase 1/2 | 260 |
| Jan 2027 (est.) | NCT06196697 AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | Ivonescimab | Phase 2 | 50 |
| Jan 1, 2027 (est.) | NCT07561463 Sacituzumab Tirumotecan for Pancreatic Cancer | Sacituzumab tirumotecan | Phase 2 | 30 |
| Jan 2027 (est.) | NCT07623577 Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases | Sacituzumab tirumotecan | Phase 2 | 24 |
| Jan 13, 2027 (est.) | NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Ivonescimab | Phase 3 | 560 |
| Jan 28, 2027 (est.) | NCT07385001 A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | Ivonescimab | Phase 1/2 | 45 |
| Jan 30, 2027 (est.) | NCT07070479 Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | Ivonescimab | Phase 2 | 208 |
| Feb 2027 (est.) | ADVANCE · NCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Orforglipron | Phase 3 | 125 |
| Feb 1, 2027 (est.) | SKB264-ANLO · NCT07388875 Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC | Sacituzumab tirumotecan | Phase 2 | 30 |
| Feb 28, 2027 (est.) | NCT07357220 A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | Ivonescimab | Phase 1/2 | 72 |
| Feb 28, 2027 (est.) | TianjinCIH · NCT07438600 Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC | Sacituzumab tirumotecan | Phase 2 | 38 |
| Mar 1, 2027 (est.) | NCT07011667 A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | CagriSema | Phase 3 | 609 |
| Mar 2027 (est.) | PROTECT-2 · NCT06992739 Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) | Sacituzumab tirumotecan | Phase 2 | 49 |
| Mar 14, 2027 (est.) | GZBF · NCT07467447 Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | Retatrutide | Phase 2 | 300 |
| Mar 24, 2027 (est.) | NCT05548127 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Vepdegestrant | Phase 1/2 | 37 |
| Mar 31, 2027 (est.) | STAR · NCT07162714 SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer | Ivonescimab | Phase 2 | 30 |
| Apr 2027 (est.) | NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | Sacituzumab tirumotecan | Phase 3 | 537 |
| Apr 2027 (est.) | NCT06925724 A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Ivonescimab | Phase 2 | 50 |
| Apr 15, 2027 (est.) | NCT07139470 Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | Sacituzumab tirumotecan | Phase 1/2 | 59 |
| Apr 30, 2027 (est.) | NCT06936644 A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation | Ivonescimab | Phase 2 | 39 |
| May 2027 (est.) | NSCLC · NCT06928389 Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | Ivonescimab | Phase 3 | 536 |
| May 2027 (est.) | NCT06670196 A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Sacituzumab tirumotecan | Phase 3 | 420 |
| May 2027 (est.) | ACHIEVE-RAM · NCT07613307 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | Orforglipron | Phase 3 | 130 |
| May 2027 (est.) | NCT06938321 A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | Ivonescimab | Phase 1/2 | 135 |
| May 2027 (est.) | NCT07009925 Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | Ivonescimab | Phase 2 | 38 |
| May 10, 2027 (est.) | NCT06074588 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Sacituzumab tirumotecan | Phase 3 | 556 |
| May 10, 2027 (est.) | NCT07052253 A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | Ivonescimab | Phase 2 | 100 |
| May 11, 2027 (est.) | NCT07655570 Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma | Ivonescimab | Phase 2 | 10 |
| May 14, 2027 (est.) | NCT06953999 A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | Ivonescimab | Phase 3 | 999 |
| May 30, 2027 (est.) | NCT07590531 AMT-116 in Combination With AK112 in Patients With Lung Cancer | Ivonescimab | Phase 1/2 | 118 |
| May 31, 2027 (est.) | NCT05379985 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Daraxonrasib | Phase 1/2 | 754 |
| Jun 2027 (est.) | TRIUMPH-8 · NCT07232719 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Retatrutide | Phase 3 | 250 |
| Jun 2027 (est.) | NCT06162221 Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Daraxonrasib | Phase 1/2 | 616 |
| Jun 2027 (est.) | NCT06922591 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Daraxonrasib | Phase 1/2 | 183 |
| Jun 1, 2027 (est.) | NCT07488572 Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | Ivonescimab | Phase 2 | 60 |
| Jun 2027 (est.) | NCT06848842 Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases | Ivonescimab | Phase 2 | 40 |
| Jun 2027 (est.) | NCT07244926 Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer | Sacituzumab tirumotecan | Phase 2 | 31 |
| Jun 9, 2027 (est.) | NCT07817251 Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | CagriSema | Phase 3 | 210 |
| Jun 11, 2027 (est.) | NCT05319730 A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | Sacituzumab tirumotecan | Phase 1/2 | 230 |
| Jun 17, 2027 (est.) | NCT06980077 Ivonescimab for the Treatment of Thymic Cancer | Ivonescimab | Phase 2 | 25 |
| Jun 20, 2027 (est.) | NCT07343479 Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases | Sacituzumab tirumotecan | Phase 2 | 45 |
| Jun 30, 2027 (est.) | NCT07188103 Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | Ivonescimab | Phase 2 | 37 |
| Jun 30, 2027 (est.) | NCT07179783 Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) | Sacituzumab tirumotecan | Phase 2 | 28 |
| Jul 2027 (est.) | NCT07071337 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | Sacituzumab tirumotecan | Phase 3 | 430 |
| Jul 1, 2027 (est.) | NCT07105852 Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma | Sacituzumab tirumotecan | Phase 2 | 59 |
| Jul 1, 2027 (est.) | NCT07789444 Sacituzumab Tirumotecan(Sac-TMT) and Brain Radotherapy for EGFR+ NSCLC With Brain Mets | Sacituzumab tirumotecan | Phase 2 | 53 |
| Jul 1, 2027 (est.) | NCT07244965 Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | Ivonescimab | Phase 2 | 42 |
| Jul 1, 2027 (est.) | I-MAC · NCT06805617 A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Ivonescimab | Phase 2 | 35 |
| Jul 1, 2027 (est.) | NCT07701122 Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer | Sacituzumab tirumotecan | Phase 2 | 33 |
| Jul 1, 2027 (est.) | NCT07630077 Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | Ivonescimab | Phase 2 | 30 |
| Jul 10, 2027 (est.) | NCT06791148 Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer | Ivonescimab | Phase 2 | 45 |
| Jul 11, 2027 (est.) | NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Sacituzumab tirumotecan | Phase 3 | 1,200 |
| Jul 15, 2027 (est.) | NCT06537011 AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | Ivonescimab | Phase 2 | 36 |
| Jul 30, 2027 (est.) | NCT07258108 Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | Sacituzumab tirumotecan | Phase 2 | 35 |
| Aug 2027 (est.) | NCT06993792 A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Orforglipron | Phase 3 | 1,400 |
| Aug 2027 (est.) | NCT06972459 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Orforglipron | Phase 3 | 800 |
| Aug 2027 (est.) | NCT06972472 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron | Phase 3 | 600 |
| Aug 2027 (est.) | NCT07114315 A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer | Ivonescimab | Phase 2 | 160 |
| Aug 1, 2027 (est.) | NCT07511504 Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | Zanzalintinib | Phase 2 | 40 |
| Aug 1, 2027 (est.) | NCT07088211 Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC | Sacituzumab tirumotecan | Phase 2 | 39 |
| Aug 1, 2027 (est.) | SENIOR-HN · NCT07094685 Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer | Ivonescimab | Phase 2 | 28 |
| Aug 3, 2027 (est.) | SEVILLA · NCT06529718 Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients | Ivonescimab | Phase 2 | 72 |
| Aug 30, 2027 (est.) | NCT07669779 A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | Ivonescimab | Phase 2 | 348 |
| Aug 30, 2027 (est.) | NCT06790212 Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer | Ivonescimab | Phase 2 | 168 |
| Aug 31, 2027 (est.) | SKB264-Fru-GA · NCT07689292 Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Sacituzumab tirumotecan | Phase 2 | 45 |
| Aug 31, 2027 (est.) | STAR-01 · NCT07501169 Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Sacituzumab tirumotecan | Phase 2 | 33 |
| Aug 31, 2027 (est.) | NCT07329322 Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Sacituzumab tirumotecan | Phase 2 | 30 |
| Sep 1, 2027 (est.) | REDEFINE 3 · NCT05669755 REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | CagriSema | Phase 3 | 7,101 |
| Sep 2027 (est.) | NCT06948422 A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | Orforglipron | Phase 3 | 974 |
| Sep 2027 (est.) | TRIUMPH-7 · NCT07035093 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Retatrutide | Phase 3 | 586 |
| Sep 2027 (est.) | NCT06948435 A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | Orforglipron | Phase 3 | 487 |
| Sep 2027 (est.) | NCT06952530 A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | Orforglipron | Phase 3 | 487 |
| Sep 1, 2027 (est.) | NCT07591090 A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | Ivonescimab | Phase 2 | 200 |
| Sep 2027 (est.) | GRACIE · NCT06846346 Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | Ivonescimab | Phase 2 | 88 |
| Sep 30, 2027 (est.) | NCT07339839 Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | Ivonescimab | Phase 1/2 | 42 |
| Sep 30, 2027 (est.) | NCT07703228 Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC | Sacituzumab tirumotecan | Phase 2 | 38 |
| Sep 30, 2027 (est.) | NCT07229417 A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | Ivonescimab | Phase 2 | 29 |
| Oct 2027 (est.) | NCT06686030 Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | Ivonescimab | Phase 2 | 150 |
| Oct 2027 (est.) | IVO Lung · NCT07204548 The IVO-LUNG Study | Ivonescimab | Phase 2 | 63 |
| Oct 12, 2027 (est.) | NCT07614984 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | Enlicitide | Phase 2 | 750 |
| Oct 31, 2027 (est.) | NCT07021950 AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | Ivonescimab | Phase 2 | 130 |
| Nov 2027 (est.) | REMBRANDT · NCT06305559 A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Obicetrapib | Phase 3 | 300 |
Stopped trials and why
Sponsors give a short reason when a trial is terminated, suspended, or withdrawn. The reason matters: a safety or efficacy stop means something very different from a business decision. See Why Do Experimental Drugs Fail?
- OLE · NCT05900141 (Pelacarsen, Phase 3, terminated): “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
- NCT07357766 (CagriSema, Phase 3, withdrawn): “The study is withdrawn due to strategic reasons.”
- NCT07625306 (Pelacarsen, Phase 3, withdrawn): “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
- Morpheus Lung · NCT03337698 (Zanzalintinib, Phase 1/2, terminated): “Study was closed early as the sponsor decided not to continue development of certain treatment combinations.”
- NCT05636267 (Ivonescimab, Phase 1/2, terminated): “Terminated due to sponsor strategic development reprioritization.”
- NCT05573555 (Vepdegestrant, Phase 1/2, terminated): “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.”
- NCT06125522 (Vepdegestrant, Phase 1/2, terminated): “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.”
- NCT04999605 (Ivonescimab, Phase 1/2, terminated): “Too low inclusion rate”
- NCT07357740 (CagriSema, Phase 2, withdrawn): “The study is withdrawn due to strategic reasons.”
- NCT07038915 (Ivonescimab, Phase 2, withdrawn): “0 participants”
- NCT07185945 (Zanzalintinib, Phase 2, withdrawn): “Funder withdrew”
- NCT06191796 (Zanzalintinib, Phase 1, terminated): “The study was terminated prior to starting the Phase 2 portion due to a business decision.”
- NCT06968988 (Zanzalintinib, Phase 1, suspended): “Protocol amendment”
- NCT04993664 (Pelacarsen, N/A, withdrawn): “Administrative reason”
Registry data can lag behind company announcements. A trial listed as active may already have reported topline results; check each drug profile for sourced updates. Not medical or investment advice. See our disclaimer.